Levetiracetam Tablet, Film Coated
Product Images NDC 63187-360

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 63187-360). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (2c7560b9 9503 43bd 811d 13f6d3957081 01)

A formula illustrating calculation of total daily dose in mL/day for medication, given by multiplying daily dose (mg/kg/day) by patient weight (kg), divided by 100 mg/mL.*

FDA Label Image

Figure 2 (2c7560b9 9503 43bd 811d 13f6d3957081 02)

A text panel showing formulas for calculating creatinine clearance (CLcr) adjusted for age, weight, serum creatinine, sex, and body surface area (BSA). Equations include factors to adjust CLcr for female patients and to normalize by BSA in mL/min per 1.73 m².*

FDA Label Image

Structure (2c7560b9 9503 43bd 811d 13f6d3957081 03)

Chemical structure of levetiracetam, the active ingredient in the product. The structure depicts the molecular configuration including a pyrrolidone ring and side chains consistent with levetiracetam's chemical composition.*

FDA Label Image

Figure 4 (2c7560b9 9503 43bd 811d 13f6d3957081 04)

A bar chart comparing the percentage of patients among three groups: placebo, levetiracetam 1000 mg/day, and levetiracetam 3000 mg/day. The chart shows approximately 7.4% of patients in the placebo group, 37.1% in the 1000 mg/day group, and 39.6% in the 3000 mg/day group. Sample sizes (N) are indicated below each group.*

FDA Label Image

Figure 5 (2c7560b9 9503 43bd 811d 13f6d3957081 05)

A vertical bar chart displaying the percentage of patients across three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). Patient sample sizes are noted beneath each group. The y-axis shows patient percentage from 0% to 45%.*

FDA Label Image

Figure 6 (2c7560b9 9503 43bd 811d 13f6d3957081 06)

A bar chart comparing the percentage of patients between two groups: one receiving placebo and the other receiving Levetiracetam 3000 mg/day. The y-axis represents the percentage of patients, with values ranging from 0% to 45%. The placebo group has a percentage of 14.4%, while the Levetiracetam group shows a higher percentage of 39.4%.*

FDA Label Image

Figure 7 (2c7560b9 9503 43bd 811d 13f6d3957081 07)

A bar chart comparing the percentage of patients between two groups: Placebo (N=97) and Levetiracetam (N=101). The chart shows approximately 19.6% for the Placebo group and 44.6% for the Levetiracetam group on the y-axis labeled '% of Patients.'*

FDA Label Image

Figure 8 (2c7560b9 9503 43bd 811d 13f6d3957081 08)

A bar chart comparing the percentage of patients between two groups: Placebo (N=51) with 19.6% and Levetiracetam (N=58) with 43.1%. The y-axis represents the percentage of patients ranging from 0% to 45%. This chart displays a comparison of patient response or outcome rates for Levetiracetam versus placebo.*

FDA Label Image

Figure 9 (2c7560b9 9503 43bd 811d 13f6d3957081 09)

A bar chart comparing the percentage of patients between two groups: Placebo (N=84) with 45.2% and Levetiracetam (N=79) with 72.2%. The y-axis represents the percentage of patients from 0% to 100%. An asterisk is shown above the Levetiracetam bar indicating statistical significance.*

FDA Label Image

63187-360-60 (2c7560b9 9503 43bd 811d 13f6d3957081 12)

Levetiracetam 500 mg film-coated tablets packaging label from Proficient Rx LP. The label displays the product name, strength, quantity (#30 tablets), and description noting each tablet contains levetiracetam USP 500 mg. It includes manufacturer information (Lupin Limited, India), storage instructions, and medication guide advisory. Several lot, serial number, expiry date, and NDC 63187-360-30 details are shown in smaller sections.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.